Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 377 results for stroke

  1. Carotid artery stent placement for symptomatic extracranial carotid stenosis (IPG389)

    Evidence-based recommendations on carotid artery stent placement for symptomatic extracranial carotid stenosis. This involves using a metal mesh called a stent to widen the narrowed carotid artery.

  2. Secondary prevention after a myocardial infarction (QS99)

    This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.

  3. Extracranial to intracranial bypass for intracranial atherosclerosis (IPG596)

    Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.

  4. Endovascular stent insertion for intracranial atherosclerotic disease (IPG429)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

  5. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

  6. Pharyngeal electrical stimulation for neurogenic dysphagia (IPG781)

    Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.

  7. Atrial fibrillation: review of anticoagulation (IND169)

    This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147

  8. What is the clinical and cost effectiveness of computer-based tools to treat problems with speech (dysarthria) and all domains of language (aphasia) for people with communication difficulties after stroke?

    domains of language (aphasia) for people with communication difficulties after stroke? Any explanatory notes(if applicable) For a short...

  9. Sickle cell disease: managing acute painful episodes in hospital (CG143)

    This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.

  10. Diabetes: T1DM and statins (IND166)

    This indicator covers the percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM142

  11. Diabetes: complications (IND9)

    This indicator covers the proportion of adults with a diagnosis of diabetes who have a recording of myocardial infarction (MI), stroke and/or end stage kidney disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG12

  12. Angina and coronary heart disease: anti-platelet or anticoagulation (IND132)

    This indicator covers the percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM88.

  13. Rheumatoid arthritis: cardiovascular risk assessment (IND108)

    This indicator covers the percentage of patients with rheumatoid arthritis (RA) aged 30 to 84 years who have had a cardiovascular risk assessment using a cardiovascular disease (CVD) risk assessment tool adjusted for RA in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM56

  14. Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism (IPG400)

    Evidence-based recommendations on thoracoscopic exclusion of the left atrial appendage in atrial fibrillation (with or without other cardiac surgery) for the prevention of thromboembolism. This involves inserting a camera and instruments through small cuts in the chest and closing the left atrial appendage.

  15. Air pollution: outdoor air quality and health (QS181)

    This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.